Compositions and methods for improving cognitive function
Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. The disorders may involve cognitive function and the methods of improving may comprise administering low doses of 5HT receptor agonists to subjects in need thereof. Improvement of the symptoms of a disorder involving cognitive function can be achieved where the disorders comprise mood, cognitive, anxiety, and depression disorders. Also disclosed herein are pharmaceutical compositions, formulations, and dosage forms of 5HT receptor agonists.
1 . A method of improving motivation or cognitive engagement in a subject in need thereof, the method comprising orally administering to the subject a pharmaceutical composition comprising:
(a) a therapeutically effective and non-hallucinogenic amount of psilocybin, wherein the psilocybin is in an amount of 0.5 mg to 4.5 mg; and
(b) a pharmaceutically acceptable inert excipient; wherein the psilocybin is the only active agent,
wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin is provided to the subject in need thereof in an amount insufficient to provide a hallucinogenic experience, and wherein the subject is an adult human and the psilocybin improves motivation or cognitive engagement in the subject without the need for constant supervision by a healthcare worker.
2 . The method of claim 1 , wherein the pharmaceutical composition is not administered as a placebo.
3 . The method of claim 1 , wherein the psilocybin is deuterated.
4 . The method of claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin is 1.5 mg to 4.5 mg.
5 . The method of claim 1 , wherein the therapeutically effective and non-hallucinogenic amount of the psilocybin is 1 mg to 4 mg.